FCMT
GALT icon

Founders Capital Management (Texas)’s Galectin Therapeutics GALT Stock Holding History

Founders Capital Management (Texas)’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000
Closed -$4K – 324
2019
Q2 		$4K Buy
+1,000
New +$4.33K ﹤0.01% 305

Other funds holding GALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Founders Capital Management (Texas)'s GALT Position: Q3 2019 in Review

Founders Capital Management (Texas) sold out of Galectin Therapeutics (GALT) in Q3 2019, closing a stake of 1,000 shares — an estimated $4K sold.

Founders Capital Management (Texas) first reported a position in GALT in Q2 2019 and held it in 1 quarter. The position peaked at $4K in Q2 2019. 80 funds tracked by Wall St. Rank hold GALT as of Q3 2019.

  • Founders Capital Management (Texas) reported no remaining Galectin Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Founders Capital Management (Texas) sold 1,000 Galectin Therapeutics shares in Q3 2019, an estimated $4K.
  • Founders Capital Management (Texas) first reported a position in Galectin Therapeutics in Q2 2019 and held it in 1 quarter.
  • Founders Capital Management (Texas)'s Galectin Therapeutics position peaked at $4K in Q2 2019.
  • 80 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2019.

Based on Founders Capital Management (Texas)'s 13F filing for Q3 2019, filed 10 Oct 2019.